Who are CM-AT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Urinary Kallikrein, C1 inhibitor (human) [C1 INH], C1 Esterase Inhibitor (Human), Prolyl Endopeptidase, Nafamostat Mesilate, Aprotinin (inhaled).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cm-at.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CM-AT — Competitive Intelligence Brief

CM-AT (CM-AT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serine protease. Area: Neurology / Psychiatry.

phase 3 Serine protease Dietary proteins / extracellular proteolysis Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

CM-AT (CM-AT) — Curemark. CM-AT is a serine protease that breaks down extracellular proteins to improve protein digestion and absorption in patients with autism spectrum disorder.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CM-AT TARGET	CM-AT	Curemark	phase 3	Serine protease	Dietary proteins / extracellular proteolysis
Urinary Kallikrein	Urinary Kallikrein	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Serine protease / Kinin-kallikrein system activator	Kininogen (substrate); B1 and B2 bradykinin receptors (downstream)
C1 inhibitor (human) [C1 INH]	C1 inhibitor (human) [C1 INH]	Shire	marketed	Complement inhibitor / Serine protease inhibitor	C1s protease / Classical complement pathway
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
Prolyl Endopeptidase	Prolyl Endopeptidase	Dr. C. Bonorino Udaondo Gastroenterology Hospital	marketed	Serine protease / Enzyme	Prolyl endopeptidase (PEP)
Nafamostat Mesilate	Nafamostat Mesilate	Chong Kun Dang Pharmaceutical	marketed	Serine protease inhibitor	Serine proteases (thrombin, factor Xa, kallikrein, trypsin)
Aprotinin (inhaled)	Aprotinin (inhaled)	Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion	phase 3	Serine protease inhibitor	Kallikrein, plasmin, trypsin, and other serine proteases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serine protease class)

Curemark · 1 drug in this class
ThromboGenics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CM-AT — Competitive Intelligence Brief. https://druglandscape.com/ci/cm-at. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab